l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway.
(2019)
Journal Article
ROBERTSON-GRAY, O.J., WALSH, S.K., RYBERG, E., JÖNSSON-RYLANDER, A.-C., LIPINA, C. and WAINWRIGHT, C.L. 2019. l‐α‐Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK‐dependent pathway. Pharmacology research and perspectives [online], 7(3), article ID e00487. Available from: https://doi.org/10.1002/prp2.487
The phospholipid l-α-lysophosphatidylinositol (LPI), an endogenous ligand for GPR55, is elevated in patients with acute coronary syndrome, and a GPR55 antagonist cannabidiol (CBD) reduces experimental ischemia/reperfusion (I/R) injury. While LPI acti... Read More about l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway..